3717 |
JANUS KINASE 2 |
JAK2 |
JTK10 |
THCYT3 |
147796 |
6192 |
ENSG00000096968 |
OTTHUMG00000019490 |
O60674 |
Tyrosine-protein kinase JAK2 |
JAK-2 |
JAK2_HUMAN |
TYROSINE-PROTEIN KINASE JAK2 (EC 2.7.1.112) (JANUS KINASE 2) (JAK-2). [SOURCE:UNIPROT/SWISSPROT;ACC:O60674] |
BE0002408 |
JAK2 V617F |
JAK1/2 |
28 |
2048 |
NM_004972 |
NP_004963 |
T08391 |
Target Class | Enzymes |
Target Subclass | EC:2.7.10.2 |
Initial Gene Query | JAK |
Counted Citations from 1950-2000 | 3125 |
Interpro Acc | IPR001245 |
Human Readable Name | KINASE |
Human Readable Name | DRUGGABLE GENOME |
Uniprot Status | Swiss-Prot |
Uniprot Evidence | 1: Evidence at protein level |
Interpro Type | Domain |
Interpro Short Name | Ser-Thr/Tyr_kinase_cat_dom |
Interpro Name | Serine-threonine/tyrosine-protein kinase catalytic domain |
GuideToPharmacology Gene Category Name | Janus kinase (JakA) family |
GuideToPharmacology Gene Category ID | 581 |
Gene Biotype | PROTEIN_CODING |
KINASE |
TYROSINE KINASE |
DRUG RESISTANCE |
DRUGGABLE GENOME |
CLINICALLY ACTIONABLE |
ENZYME |
inhibitor (inhibitory) |
Novel drug target | Novel Target |
Trial Name | AC430 |
Direct Interaction? | False |
inhibitor (inhibitory) |
Indication/Tumor Type | hematologic cancer |
Response Type | decreased response |
Approval Status | Preclinical |
inhibitor (inhibitory) |
Mechanism of Interaction | Tyrosine-protein kinase JAK2 inhibitor |
Direct Interaction | yes |
Specific Action of the Ligand | Inhibition |
inhibitor (inhibitory) |
Mechanism of Interaction | Tyrosine-protein kinase JAK2 inhibitor |
Direct Interaction | yes |
Specific Action of the Ligand | Inhibition |
inhibitor (inhibitory) |
Direct Interaction? | True |
Endogenous Drug? | False |
Specific Action of the Ligand | Inhibition |
inhibitor (inhibitory) |
Response Type | resistant |
Evidence Type | Actionable |
Approval Status | Preclinical |
inhibitor (inhibitory) |
Mechanism of Interaction | Tyrosine-protein kinase JAK2 inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Evidence Type | Actionable |
Approval Status | Preclinical |
Response Type | resistant |
inhibitor (inhibitory) |
Trial Name | SB1518, ONX 0803 |
Novel drug target | Novel Target |
Mechanism of Interaction | Tyrosine-protein kinase JAK2 inhibitor |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | True |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Tyrosine-protein kinase JAK2 inhibitor |
Specific Action of the Ligand | Inhibition |
inhibitor (inhibitory) |
Direct Interaction? | True |
Endogenous Drug? | False |
Specific Action of the Ligand | Inhibition |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
antagonist (inhibitory) |
inhibitor (inhibitory) |
Direct Interaction? | True |
Endogenous Drug? | False |
Specific Action of the Ligand | Inhibition |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | True |
inhibitor (inhibitory) |
Mechanism of Interaction | Tyrosine-protein kinase JAK2 inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Tyrosine-protein kinase JAK2 inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
inhibitor (inhibitory) |
Trial Name | lestaurtinib, CEP-701 |
Novel drug target | Novel Target |
Indication/Tumor Type | hematologic cancer |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | True |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
inhibitor (inhibitory) |
Direct Interaction? | False |
Endogenous Drug? | False |
Specific Action of the Ligand | Inhibition |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
inhibitor (inhibitory) |
Mechanism of Interaction | Janus Kinase (JAK) inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Direct Interaction? | False |
Endogenous Drug? | False |
Specific Action of the Ligand | Inhibition |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
inhibitor (inhibitory) |
Mechanism of Interaction | Tyrosine-protein kinase JAK2 inhibitor |
Direct Interaction | yes |
Specific Action of the Ligand | Inhibition |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
inhibitor (inhibitory) |
Direct Interaction? | False |
Endogenous Drug? | False |
Specific Action of the Ligand | Inhibition |
n/a |
Trial Name | ENMD-2076 |
Novel drug target | Novel Target |
inhibitor (inhibitory) |
Details of the Assay for Interaction | Binding to the JH2 pseudo kinase domain of JAK2 was determined using isothermal titration calorimetry (ITC). |
Specific Action of the Ligand | Binding |
Endogenous Drug? | False |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
JAK2 | Ensembl Gene Name |
Gene Biotype | PROTEIN_CODING |
JAK2 | Gene Symbol |
Target Class | Enzymes |
Target Subclass | EC:2.7.10.2 |
TYROSINE-PROTEIN KINASE JAK2 (EC 2.7.1.112) (JANUS KINASE 2) (JAK-2). [SOURCE:UNIPROT/SWISSPROT;ACC:O60674] | Description |
ENSG00000096968 | Ensembl Gene Id |
JAK2 | Display Id |
Human Readable Name | DRUGGABLE GENOME |
DRUGGABLE GENOME |
3717 | Entrez Gene ID |
Initial Gene Query | JAK |
Counted Citations from 1950-2000 | 3125 |
KINASE |
3717 | Entrez Gene Id |
JAK2 | Uniprot Gene Name |
ENSG00000096968 | Ensembl Gene Id |
Interpro Acc | IPR001245 |
Human Readable Name | KINASE |
Human Readable Name | DRUGGABLE GENOME |
KINASE, DRUGGABLE GENOME |
6192 | HUGO Gene ID |
6192 | HUGO Gene Symbol |
Janus kinase 2 | HUGO Gene Name |
GuideToPharmacology Gene Category Name | Janus kinase (JakA) family |
GuideToPharmacology Gene Category ID | 581 |
ENZYME |
3717 | CKB Entrez Id |
JAK2 | CKB Gene Synonym |
JTK10 | CKB Gene Synonym |
3717 | Entrez Gene ID |
28 | CIViC Gene ID |
DRUG RESISTANCE |
JAK2 | DrugBank Gene Name |
O60674 | UniProt Accession |
3717 | Entrez Gene Id |
ENSG00000096968 | Gene Symbol |
JAK2 | Ensembl Id |
DRUGGABLE GENOME |
JAK2 | Gene Symbol |
3717 | Entrez Gene Id |
JAK2 | MyCancerGenome Gene Symbol |
JAK2 | MyCancerGenome Reported Gene Name |
JAK-2 | UNIPROT |
JAK2 | GENE_SYMBOL |
Tyrosine-protein kinase JAK2 | UNIPROT |
3717 | OncoKB Entrez Id |
THCYT3 | OncoKB Gene Synonym |
JTK10 | OncoKB Gene Synonym |
Tyrosine-protein kinase JAK2 | Gene Name |
O60674 | UniProt ID |
KINASE |
JAK2 | Gene Symbol |
CLINICALLY ACTIONABLE |
3717 | Gene ID |
JTK10 | dGene Synonym |
THCYT3 | dGene Synonym |
KINASE, TYROSINE KINASE |
JAK-2 | TTD Gene Abbreviation |
T08391 | TTD Target ID |
CLINICALLY ACTIONABLE |
CLINICALLY ACTIONABLE |
CLINICALLY ACTIONABLE |
TYROSINE KINASE |
CLINICALLY ACTIONABLE |
DRUG RESISTANCE |